Session 1 | Session 2 | Session 3 | Session 4

Thursday, October 14, 2021

Session 1: Smarter Solid Form & Pre-formulation Studies

US EDT	UK DT	Beijing CST	Keynote Presentations & Activities
08:00 - 08:10	13:00 – 13:10	20:00 - 20:10	Greetings and opening speech by Chairman, Dr. San Kiang, J-Star Research/Porton
08:10 - 08:15	13:10 – 13:15	20:10 – 20:15	Session 1: Smarter Solid Form & Pre-formulation Studies Introduction by Moderator, Dr. Shanming Kuang, J-Star Research/Porton
08:15 - 09:05	13:15 – 14:05	20:15 - 21:05	Development of a Green and Sustainable Manufacturing Process for Gefapixant Citrate (MK-7264): A Solid-State Chemistry Perspective Dr. Alfred Lee, Merck Research Laboratories
09:05 - 09:55	14:05 - 14:55	21:05 - 21:55	What Solid Form Should I Choose? Dr. Ann Newman, Seventh Street Development Group
09:55 -10:15	14:55 - 15:15	21:55 – 22:15	Coffee/Tea Break
10:15 – 11:05	15:15 - 16:05	22:15 – 23:05	Understanding and Controlling the API Form/Powder Property Risks in Drug Substance and Product Processes Dr. Shawn Yin, Bristol-Myers Squibb
11:05 – 11:55	16:05 - 16:55	23:05 - 23:55	Absolute Structure Determination of API Molecules by MicroED Analysis of Co-Crystals Formed Based on COSMO-RS Prediction Drs Chandler Greenwell (XtalPi), Harsh Shah (CfPC/J-Star/Porton), and Jessica Bruhn (NIS).
11:55 – 12:00	16:55 - 17:00	23:55 – 24:00	Closing Remarks by session moderator

Thursday, October 14, 2021

Session 2: Particle Engineering & DS-DP Co-Processing

US EDT	UK DT	Beijing CST	Keynote Presentations & Activities
13:00 – 13:05	18:00 - 18:05	01:00 - 01:05	Session 2: Physical Property Based Crystallization Process Development Introduction by Moderator, Dr. San Kiang, J-Star Research/Porton
13:05 – 13:55	18:05 – 18:55	01:05 - 01:55	Examples of Particle Engineering to Improve Patient Outcomes and Product Manufacturing Dr. Christopher Burcham, Eli Lilly and Company
13:55 – 14:45	18:55 - 19:45	01:55 - 02:45	Crystal habit modifications and spherical crystallization design in solution Prof. Junbo Gong, Tianjin University
14:45 – 15:05	19:45 – 20:05	02:45 – 03:05	Coffee/Tea Break
15:05 – 15:55	20:05 - 20:55	03:05 - 03:55	Challenges and Opportunities in Optimizing Mechanical Properties of Drugs by Incorporating Excipients Prof. Calvin Changquan Sun, University of Minnesota
15:55 – 16:45	20:55 - 21:45	03:55 - 04:45	Bridging the Gap between Drug Substance and Drug Product Productions via Co-Processing Dr. Jian Wang, CfPC/J-Star Research/Porton
16:45 - 16:50	21:45 - 21:50	04:45 - 04:50	Closing Remarks by session moderator

Friday, October 15, 2021

Session 3: Physical Property Based Crystallization Process Development

US EDT	UK DT	Beijing CST	Keynote Presentation
08:10 - 08:15	13:10 – 13:15	20:10 - 20:15	Session 3: Particle Engineering and DS-DP Co-Processing Introduction by Moderator, Dr. Yuriy Abramov, XtalPi
08:15 - 09:05	13:15 – 14:05	20:15 - 21:05	The Importance of Understanding and Characterising the Physical & Chemical Properties of APIs in the Digital Design of Drug Products Prof. Kevin Roberts, University of Leeds
09:05 - 09:55	14:05 - 14:55	21:05 - 21:55	Continuous Crystallization and Purification: The Role of Impurity Incorporation Mechanism in Non-Equilibrium Processes Prof. Allan Myerson, Massachusetts Institute of Technology
09:55 -10:15	14:55 – 15:15	21:55 – 22:15	Coffee/Tea Break
10:15 – 11:05	15:15 - 16:05	22:15 – 23:05	Co-Crystals Platform to Improve Physical Properties of Early Intermediates during API Manufacturing Process Dr. Samir Kulkarni, Pfizer
11:05 – 11:55	16:05 - 16:55	23:05 – 23:55	Correlation of Solubility with the Metastable Limit Prof. Ken Morris, Long Island University
11:55 – 12:00	16:55 - 17:00	23:55 – 24:00	Closing Remarks by session moderator

Friday, October 15, 2021

Session 4: Topical Panel Discussions

US EDT	UK DT	Beijing CST	Keynote Presentation
13:00 – 13:10	18:00 – 18:10	01:00 – 01:10	Session 4: Topical Panel Discussions Introduction by Chairman, Dr. San Kiang, J-Star Research/Porton
13:10 – 13:45	18:10 – 18:45	01:10 – 01:45	Potentials and Technologies to Increase Success Rate of Polymorph Screening Moderator: Dr. Alfred Lee, Merck Research Laboratories
13:45 – 14:20	18:45 – 19:20	01:45 – 02:20	Overcoming Industrial Challenges in Implementation of Crystallization Technologies Moderator: Dr. Kevin Girard, Pfizer
14:20 – 14:55	19:20 – 19:55	02:20 – 02:55	Realizing Regulatory Challenges in Applying Crystallization Technologies Moderator: Dr. Christopher Burcham, Eli Lilly and Company
14:55 – 15:00	19:55 – 20:00	02:55 – 03:00	Closing Remarks by Chairman, Dr. San Kiang, J-Star Research/Porton (end of webcasting)